Globally, hypertension has become one of the most common chronic diseases, affecting more than 1 billion people. Long-term elevated blood pressure not only damages the heart, blood vessels, and kidneys, but also significantly increases the risk of serious cardiovascular events such as myocardial infarction, stroke, and heart failure.

However, because hypertension often presents without obvious symptoms, many patients fail to receive timely intervention in the early stages of the disease, leading to long-term poor blood pressure control.

Hypertension is a clinical syndrome mainly characterized by elevated systemic arterial pressure and increased peripheral arteriolar resistance. Its diagnostic criteria are: in the absence of antihypertensive medication, clinic blood pressure ≥140/90 mmHg; or home blood pressure ≥135/85 mmHg; or 24-hour ambulatory blood pressure ≥130/80 mmHg (daytime ≥135/85 mmHg, nighttime ≥120/70 mmHg). If long-term hypertension is not effectively controlled, it can lead to severe complications such as cerebral hemorrhage, heart failure, chronic renal failure, and aortic dissection, and may even be life-threatening, imposing heavy health and economic burdens on individuals, families, and society.

Hypertension Treatment Concepts Are Evolving

In the past, hypertension treatment typically started with a single antihypertensive drug, with dosage gradually increased or additional medications added based on therapeutic response. However, a growing number of studies suggest that for patients at moderate to high risk or with significantly elevated blood pressure, early combination therapy can achieve target blood pressure more quickly and more consistently.

Fixed-dose combination therapies have therefore gained increasing attention. These medications integrate two antihypertensive agents with different mechanisms of action into a single tablet, which not only enhances the blood pressure-lowering effect but also reduces the number of pills patients must take, thereby improving treatment adherence.

Telmisartan hydrochlorothiazide tablets represent a typical example of this therapeutic strategy and are widely used worldwide for the combination treatment of hypertension.

Clinical Studies Confirm Efficacy and Tolerability

DengYueMed, which has long focused on global cardiovascular disease treatment and innovative drug development trends, notes that hypertension, as a highly prevalent chronic cardiovascular disease worldwide, has become one of the major public health threats to human health. In recent years, hypertension in China has been characterized by a “high prevalence rate, low awareness rate, low treatment rate, and low control rate.” At the same time, the development, clinical application, and market landscape of antihypertensive drugs continue to evolve, with a new generation of innovative therapies gradually overcoming the limitations of traditional treatments and offering more precise and safer therapeutic options for patients.

Publicly available data show that as of March 2026, the standardized management rate of hypertension in China has steadily improved, but a large number of patients still have not received effective treatment. Innovation in antihypertensive drug development and improved accessibility have therefore become key priorities for the industry.

Multiple randomized controlled studies have demonstrated that compared with ARB monotherapy or diuretics alone, the combination therapy of telmisartan and hydrochlorothiazide significantly improves the rate of blood pressure control.

In multicenter clinical studies, patients receiving fixed-dose telmisartan/hydrochlorothiazide combination therapy showed significantly greater reductions in systolic and diastolic blood pressure compared with the monotherapy group. In addition, long-term follow-up data indicate that this combination regimen can maintain stable blood pressure control over a 24-hour period, especially during the early morning blood pressure surge, which is of great importance in preventing cardiovascular and cerebrovascular events.

Trends in Antihypertensive Drug Development: Innovation-Driven, Focused on Precision and Safety

Although traditional antihypertensive drugs can effectively control blood pressure, they still have certain limitations, such as drug resistance in some patients, significant inter-individual differences in efficacy, notable adverse reactions, and the need for long-term medication. These challenges continue to drive the pharmaceutical industry to explore a new generation of antihypertensive drugs that are safer, more effective, and more convenient. Based on publicly available information from the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China and global R&D trends, current antihypertensive drug development shows three major trends. The relevant data are derived from publicly available R&D reports and clinical study results:

1.  Accelerated development of drugs targeting novel mechanisms:

Traditional antihypertensive drugs mainly target classical pathways such as the renin-angiotensin system, calcium channels, and β-adrenergic receptors. The new generation of antihypertensive drugs focuses on novel targets, such as renin receptor antagonists and endothelin receptor antagonists. These drugs offer stronger specificity, more pronounced blood pressure-lowering effects, and better protection of target organs such as the heart, brain, and kidneys. As of March 2026, several novel antihypertensive drugs in China have entered clinical development, including two in Phase III trials and one in Phase II trials. Early clinical data show that their antihypertensive efficacy is 10%–15% higher than that of traditional drugs, while the incidence of adverse reactions is reduced by more than 20%.

2.  Combination formulations becoming a major R&D focus:

Combination antihypertensive drugs integrate two or more agents with different mechanisms of action, reducing the number of medications patients must take, improving adherence, and achieving synergistic blood pressure control. Currently, more than 30 combination antihypertensive drugs have been approved in China. Clinical data indicate that combination formulations can increase the blood pressure control rate by 15%–20% compared with monotherapy, while patient adherence improves by more than 30%. In the future, the development of combination formulations will place greater emphasis on “personalized combinations,” designing specific regimens for patients with different comorbidities.

3.  Precision medicine and individualized treatment are becoming a reality:

With the advancement of genetic testing technologies, antihypertensive drug development is gradually moving toward precision medicine. By analyzing patients’ genetic profiles, clinicians can determine their sensitivity to different antihypertensive drugs and achieve individualized therapy. Clinical studies have shown that gene-guided individualized antihypertensive therapy can increase the blood pressure control rate to over 85% while reducing the incidence of adverse reactions. This approach is particularly suitable for patients with multiple underlying diseases or those who are less responsive to conventional antihypertensive drugs. Currently, some medical institutions in China have begun pilot programs using genetic testing to guide individualized hypertension treatment, and related technologies are gradually being promoted.

Key Areas of Industry Focus for Hypertension Control and Antihypertensive Drug Development in China

In recent years, China’s biopharmaceutical industry has continuously increased its R&D investment in cardiovascular diseases. More and more companies are entering the field of innovative antihypertensive drug development. Meanwhile, national policies are also being improved to strengthen hypertension prevention and control while enhancing drug accessibility. DengYueMed believes that hypertension control and antihypertensive drug development are key areas in the global cardiovascular disease treatment landscape. Based on current industry trends, three major aspects deserve particular attention in the future:

Improving standardized hypertension management at the primary care level:

To address the low awareness and treatment rates of hypertension in primary care settings, the government is promoting the availability of comprehensive antihypertensive medications in primary medical institutions, strengthening healthcare professional training, and implementing nationwide blood pressure screening programs—particularly targeting younger and middle-aged populations—to achieve early detection, diagnosis, and treatment. It is estimated that by 2030, China’s hypertension awareness rate will increase to over 70%, the treatment rate to over 60%, and the control rate to over 30%.

Promoting innovation and translation in antihypertensive drug development:

Encouraging pharmaceutical companies to increase investment in the development of new antihypertensive drugs, focusing on novel targets, combination formulations, and long-acting dosage forms, while accelerating clinical development to bring innovative therapies to market sooner. In addition, through centralized procurement and national medical insurance negotiations, the cost of innovative antihypertensive drugs can be reduced, improving accessibility and allowing more patients to benefit.

Strengthening health education and patient management:

By disseminating knowledge on hypertension prevention and treatment through multiple channels, the public can be encouraged to adopt healthy lifestyles such as low-salt diets, regular exercise, smoking cessation, and limited alcohol consumption, thereby reducing the risk of hypertension. At the same time, long-term management of patients with hypertension should be strengthened, guiding them to adhere to standardized medication regimens and regularly monitor blood pressure to improve treatment adherence and reduce the occurrence of complications.

Conclusion

Overall, China faces a large population of patients with hypertension and a challenging prevention and control situation. However, with continuous innovation in antihypertensive drug development, the improvement of prevention and control policies, and growing public health awareness, the control rate of hypertension is expected to gradually increase in the future. DengYueMed will continue to monitor global trends in antihypertensive drug development and hypertension prevention and control, providing medical institutions and patients with cutting-edge treatment information and high-quality antihypertensive drug supply services through its international pharmaceutical supply platform, and contributing to the high-quality development of hypertension prevention and control in China.